4.5 Review

Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 64, Issue -, Pages S535-S546

Publisher

IOS PRESS
DOI: 10.3233/JAD-179942

Keywords

Aggregation; Alzheimer's disease; conformational ensemble; immunotherapy; tau protein; truncation

Categories

Funding

  1. VEGA grant [2/0177/15]
  2. EU structural funds [ITMS 26240220008]
  3. Axon Neuroscience SE

Ask authors/readers for more resources

Tau protein plays a major role in the pathogenesis of Alzheimer's disease. Despite many decades of intensive research, the cause of the conformational switch that leads to the remodeling of the highly flexible conformational ensemble of intrinsically disordered protein tau into insoluble filaments is still elusive. We show here that truncation of tau may play a causative role in this conformational change, as evidenced by results obtained from in vitro experiments and from transgenic animal models. This conformational change is a common denominator of pathological tau protein assemblies, and a salient drug target. The long-running research of truncated tau has led to the generation of the first active tau vaccine that has entered clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available